In the Margins

Sequoia Fund manager details Valeant experience

March 1, 2016

By Barron's

In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.

 

 

Most Read

Top of the Agenda - Compensation
IDC study: Director pay up more than 5% in 2022

Independent mutual fund directors earned more in 2022 than they did in 2021, according to industry data obtained by Fund Board Views. The year-on-year increase—a median of ...